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When I first learned that I was to give this talk, I looked
back at my predecessors to see what they had done. I
found basically three prototypes: first, the straightforward
scientific talk on the subject of one’s work; second, the
philosophical talk that tries to either interpret the past or
predict the future of genetics; and third, the autobiograph-
ical talk that discusses the processes that shaped one’s own
career. Being bored with the first and not philosophical
enough for the second, I have opted for the third. This
year marks the 50th anniversary of the first description of
the correct human chromosome number.1 Although I am
sure you all think I remember when the number was 48,
I have to disappoint you: I actually do not. However, I do
remember when we didn’t know that Down syndrome was
the result of an extra chromosome. Diagnosis of a new-
born often involved something called “dermatoglyphics,”
where one calculated a Bayesian likelihood that the child
had what was then called “Mongolism” by scoring a set
of finger and palm print patterns. I hope that my talk will
both give the younger folk a feeling for how cytogenetics
has progressed in successive stages and also be a nostalgic
walk along memory lane for the older folks in the audience.
The phrase in my title, “Having It All,” is traditionally
used as a description of a lifestyle, implicitly by a woman,
that tries to combine career and family life without short-
changing either one. The phrase does apply to my life in
the usual sense, and I shall return to this at the end of
my talk.
However, I chose the phrase because it also seemed to
describe my life in human genetics in several other ways.
First, cytogenetics has allowed me to combine two seem-
ingly disparate enthusiasms: the part of me that likes to
play around in the laboratory with new techniques and
the part that likes to sit at my calculator or computer and
play around with numbers. Secondly, “Having It All” can
also be used as a metaphor for the achievement of the
Human Genome Project, which I have also seen come to
fruition since attending the first human gene–mapping
conference in 1973. Thirdly, I have been able to have it
all in another sense, by combining both clinical and re-
search activities during almost 40 years of directing a clin-
ical cytogenetics lab in an academic setting.
My father was a chemist, and I owe him much in giving
me an early love of science and the expectation that I
could excel in it even though I was female. He bought me
chemistry sets and other scientific toys, but he had a strict
rule that no chemistry experiments were to be done by
me without his presence. I suppose as an attempt to make
me cautious, he told me stories about the dangers of each
compound in my set, what they should not be mixed with,
and how they could be used to physically damage either
myself or the environment. As a result, he unfortunately
instilled in me a fear and dislike of chemistry that persists
to this day. I studied biology in college, not only because
it was naturally appealing to me because of my love of
natural history, but also because it seemed at that time a
science fairly free of chemistry. I had discovered I enjoyed
mathematics, and part of the appeal of genetics, in which
I majored, was that it was a science that dealt in mathe-
matical ratios and experiments that involved counting. I
then discovered, under the tutelage of my first mentor,
Clarke Fraser at McGill University in Montreal, that there
was something called “human genetics” that was even free
of experimentation and, at that time, rarely involved labs.
This was very attractive to me, and I ended up writing a
Ph.D. thesis in human genetics that did not involve ever
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Table 1. Minute Deletions by Consensus9
Sample
No.
of
Cells
Percentage of Cells Judged to
Show a Deletion by Observer
O.J.M. P.W.A. D.W. D.A.M.
Normal 84 17 34 11 21
Case 28a 70 47 74 33 64
Father of case 28 77 25 32 16 31
Known deletiona 18 100 94 94 100
NOTE.—O.J.M. is Orlando J. Miller, P.W.A. is Penny W. Allder-
dice, D.W. is Dorothy Warburton, and D.A.M. is D. Anne Miller.
a Statistically significantly higher than normal control for all
observed.
lifting a pipette but instead dealt with statistical and ep-
idemiological analysis of family data.
My problem was that my thesis topic was the role of
genetics in spontaneous abortions, and I finished it in
1961, just after the discovery of the first human cytoge-
netic abnormalities by Lejeune, Jacobs, and others. At that
time, we knew nothing about the importance of chromo-
some abnormalities in embryonic and fetal loss, though,
in looking back at the paper published from my thesis, I
see that the idea did actually occur to me as a possibility
to explain the maternal-age association.
It is possible that the effect of parental age is due to
an increase in chromosomal aberrations, rather than in
genic mutations….
[I]n female germ cells…terminalization of chiasmata
might increase with maternal age. Terminalization of
chiasmata leads to reduced efficiency in pairing of
the chromosomes, with subsequent increase in the fre-
quency of nondisjunction. Thus older mothers might
have an increased probability of producing gametes
with abnormal chromosome complements….2(p17–18)
Soon after, Carr in Canada3 and Szulman in the United
States4 first reported the major role that chromosome ab-
normalities played in causing miscarriages. If I was to con-
tinue in this field, I needed to learn cytogenetics. Although
Clarke and I did succeed in making the first human chro-
mosome preparations at McGill in 1960, I was still not
convinced that the laboratory was a place where I would
ever feel at home.
In 1963, my husband accepted a job at Barnard College
in New York City. I was lucky to find a position in the
Department of Obstetrics and Gynecology at Columbia
University with Orlando J. Miller (known familiarly as
“Jack”), who agreed to teach me cytogenetics and let me
work on spontaneous abortions if I wished. I was finally
working in a lab and discovered that I enjoyed it. Cyto-
genetics was much more like cooking than chemistry, and
I had always enjoyed cooking.
At the time, chromosomes were not banded, and only
chromosome groups (A, B, C, D, E, F, and G) could be dis-
tinguished reliably. However, it had been discovered that
chromosome pairs with similar morphology often repli-
cated asynchronously.5,6 This could be studied by adding
tritiated thymidine to cultured cells at the end of the S
phase. Incorporated radioactivity was then detected by
dipping metaphase slides in photoemulsion, leaving them
for several weeks in the dark, developing the film, and
counting silver grains.
So, my passion for numbers was to be satisfied again.
Jack, his wife, Sandy, Roy Breg, and I had identified a large
number of patients with a deletion of a B-group short arm.
We showed that the deleted chromosome in patients with
features of cri-du-chat syndrome consistently replicated
earlier than the deleted chromosome in patients with the
features of Wolf-Hirschhorn syndrome. Furthermore, by
measuring chromosomes with a map measurer, we showed
that the chromosome that replicated earlier was shorter
than the one that replicated later. Thus, cri-du-chat could
be defined as due to a deletion of the short arm of chro-
mosome 5, and Wolf-Hirschhorn syndrome was due to a
deletion of chromosome 4.7 It was tedious, and, in the
end, futile, but it worked. The same process was used to
define the deleted large acrocentric chromosome in two
patients with a similar phenotype as chromosome 13.8
We also used a statistical approach in what was probably
the first example of microdeletion analysis.9 To settle ar-
guments in the lab about whether certain patients really
had small deletions of a B-group short arm, we random-
ized photos of metaphase spreads from these patients,
along with positive and negative controls, and had several
observers assess which cells had a B-group chromosome
with a short-arm deletion. We then tabulated the data by
assessor; table 1 is representative of the interesting results.
Whereas scorers varied in the number of normal cells they
concluded had deletions, they all agreed on which cases
had a larger number of cells with a deletion than did nor-
mal controls. This “blind cytogeneticist” approach might
still be useful when trying to assess those cases, which still
occur, when there is argument in the lab about whether
some subtle chromosome rearrangement is really present.
Of course, these days, we can usually find other more el-
egant ways to settle such arguments.
After some years of these kinds of heroic efforts to ex-
tract more information from unbanded karyotypes, an
end of all scientific interest in human cytogenetics was
forecast for the first, but not the last, time. Then banding
patterns were discovered, and everything changed.
Quinacrine banding allowed us, for the first time, to
identify all individual chromosome pairs and to detect
many more rearrangements. This was essential for the first
associations of genes and linkage groups with individual
chromosomes and was thus the first step in the Human
Genome Project. Banding was first described in 1970.10 By
1973, the first human gene–mapping conference was held
at Yale, at which a total of 19 genes were assigned to chro-
mosomes, some of them, as it turned out, incorrectly.11
Since, with existing fluorescent microscopic equipment,
photographing a Q-banded metaphase might require a 2-
min exposure, cytogeneticists all spent a good deal of time
sitting in the dark. G banding was thus a major break-
through. I was fortunate enough to have a super techni-
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Table 2. rDNA Sites in the Great Apes
Human Homologue Human Chimpanzee Gorilla Orangutan
2p    
2q    
9    
13    
14    
15    
18    
21    
22    
Total no. of sites 5 5 2 9
NOTE.—A minus sign () p no rDNA genes; a plus sign () p
rDNA genes present. Shaded areas are regions of difference from the
human sites.
cian, Saundra Villafane, who devised a reliable G-banding
method that we quickly adopted in the clinical laboratory.
It is now hard to believe, but, at the time, there was an
argument among cytogeneticists as to whether Q banding
or G banding was better and whether banding needed to
be adopted by all labs doing clinical work. Saundra and I
were often invited to other labs to demonstrate our band-
ing method. All of you who work in labs (or kitchens) will
know that when you perform a technique in someone
else’s space, it usually doesn’t work: this was certainly true
for our banding method.
Nevertheless, I was invited to the Paris Conference on
Chromosome Nomenclature, where we drew up the initial
banding diagrams. Given the preparations we had to work
with, it is impressive that these diagrams were so accurate
and useful for so long. The meeting was held at a very
undistinguished hotel near Orly Airport, where one could
not even go out for a walk in pleasant surroundings. The
March of Dimes, who financed the meeting, worked us
hard from morning to evening. Here I was, relatively
young and in Paris for the first time, but I did not actually
see the city until 3 days later when the meeting was over.
There were many national and personal rivalries involved
in coming to any consensus. For example, the French used
R banding, and most of the rest of the world used G band-
ing, so a major problem was to decide which bands had
priority in the nomenclature system. Luckily, our chair-
man, John Evans, who was a very strong-minded Welsh-
man with a booming voice, came up with the brilliant
idea that there should not be bands with interbands in
between but rather that both dark and light bands should
be given equal weight in the numbering system.
A band is…part of a chromosome which is clearly
distinguishable from its adjacent segments by appearing
darker or lighter…. The chromosomes are visualized as
consisting of a continuous series of light and dark bands,
so that by definition there are no “interbands.”12(p6)
Otherwise, it might have been even longer before I saw
Paris!
Banding analysis opened up a whole new continent for
exploration, as we identified many new kinds of chro-
mosome aberrations in humans that had previously been
shown only in experimental organisms. Larry Shapiro and
I described the first human insertion13 and also one of the
first human dicentric chromosomes, which we showed
had only one centromere that remained as a constriction
as metaphase proceeded.14
Another technical innovation was the discovery, by Joe
Gall and Marylou Pardue,15,16 that nucleic acid hybridiza-
tion would occur on chromosomes fixed on a slide, some-
thing not at all intuitively obvious. Kim Atwood, Adjie
Henderson, and I set out to apply this for the first time
to humans. It was not easy. Recombinant DNA technol-
ogies had been banned, so that labeled probe had to be
produced by growing cells in the presence of tritiated uri-
dine and by extracting the RNA. Because of the low spe-
cific activity of the probes that could be produced, only
repetitive sequences could be mapped, and exposure times
were at least a month. Again, my statistical inclinations
were satisfied, as one had to count the silver grains over
all chromosomes and perform statistical analysis in order
to distinguish real label from background. How different
from the practically instant gratification provided by FISH!
In 1972, we published the first localization of human
genomic sequences by in situ hybridization,17 establishing
that the 18–28S ribosomal genes were on the short arms
of all the acrocentric chromosomes, as had been suggested
much earlier by Malcolm Ferguson-Smith based on other
evidence.18 We also showed that the copy number of these
sequences could vary a great deal among chromosomes
and that this was associated with behavior, such as satellite
associations in metaphase.19 We then set out to compare
the localization of rDNA in multiple primate species. Since
most of these had not been G banded, we had to work
out the karyotypes first. Although we wrote one of the
first papers comparing the human and chimpanzee G-
banded karyotypes, it was turned down by Science because
it was “not of general interest.”20 We did succeed in show-
ing that the rDNA regions in primates had evolved in a
rather complex pattern, as illustrated in table 2. No two
of the great apes were alike. For example, chromosome 15
contained sites only in the human and orangutan, while
only the small acrocentrics contained rDNA sites in the
two species of gorilla.21
Meanwhile, I had not forgotten my interest in miscar-
riages or epidemiology. In the 1970s, I began a collabo-
ration that would last for many years with Dr. Zena Stein,
an epidemiologist interested in Down syndrome. Together
with Mervyn Susser, Zena and I had the idea that a search
for factors influencing the frequency of trisomy 21 could
be done much more efficiently by ascertaining all triso-
mies from a collection of spontaneous abortions. I learned
much from my association with colleagues who did real
epidemiology, as opposed to my seat-mof-the-pants ap-
proach. This included my first exposure to the notion of
statistical power: contrary to intuition, it is easier to detect
an increase in an entity that occurs commonly than in
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Table 3. Statistical Power in Environmental Monitoring: Detecting a Doubling in the
Frequency of Trisomy
Outcome
Prevalence of the
Outcome in
Sample Size (per Group)
Requireda
Unexposed Exposed 80% Power 90% Power
Down syndrome in live births .0014 .0028 18,183 23,874
All trisomies in live births .0033 .0066 7,693 10,100
Spontaneous abortions in pregnancies .15 .21 675 893
Trisomies in karyotyped spontaneous abortions .40 .57 146 191
* At , two-tailed.ap .05
one that occurs rarely (table 3). To have a 90% chance of
observing a doubling of the frequency of trisomy at birth,
it would take more than 23,000 births in the exposed and
unexposed groups. For the same power, it would take only
893 pregnancies scored as term or miscarriage or 191 kar-
yotyped spontaneous abortions to detect a doubling of
the frequency of trisomy at conception. We therefore set
out on a 10-year study to examine the role of environ-
mental and other factors in the etiology of aneuploidy
and other chromosome aberrations. We ascertained all
women having spontaneous abortions in three Manhattan
hospitals, karyotyped their fetal tissue, and interviewed
women with karyotyped spontaneous abortions, along
with an age-matched control of women with live births.
To control for recall bias, we used as a secondary control
the women with chromosomally normal spontaneous
abortions, since women did not know the karyotype of
their pregnancy losses at the time of interview. The project
director of this study was a graduate student, Jennie Kline,
who stayed on at Columbia and has remained my col-
league on studies of chromosomes in reproduction ever
since.
This study was essentially negative, in that it failed to
identify any factors associated with chromosome aberra-
tions at conception.22–24 The only consistent positive find-
ing was the association of trisomy with maternal age,
which was well known for trisomy 21 but which we could
establish was true for most other trisomies as well. At the
same time we were doing our study, Pat Jacobs and Terry
Hassold were carrying out a very similar study in Hawaii.
Many of our analyses benefited from either combining or
comparing the two studies.25,26 In spite of very different
populations in New York City, which included many Afri-
can Americans and Hispanics, and Hawaii, which included
many people of Asian and Hawaiian descent, the frequen-
cies and distribution of anomalies, as well as the maternal-
age curves for individual trisomies, were very similar. Both
studies, for example, showed a linear curve relating ma-
ternal age to trisomy for chromosome 16 and an expo-
nential curve like that for chromosome 21 for most other
trisomies. In both studies, trisomy 16 made up about one-
third of all trisomic conceptions, and trisomies for chro-
mosomes 1, 11, 17, and 19 were very rare or absent. This
was another indication of the general lack of any genetic
or environmental factors, except for maternal age, that
were associated with aneuploidy. The high rate of chro-
mosomal anomalies in our species seems to be built into
our biology and is not usually the result of accumulation
of adverse events.
Later studies with Jennie Kline have concentrated on
the maternal-age relationship. In mammals, all oocytes are
created in early fetal life, where they are arrested in meiotic
prophase. The first meiotic division is completed only at
the time of ovulation. The nature of the change that oc-
curs during this long resting period to cause the increase
in error rate in older women is still unknown. We carried
out two studies to test the hypothesis that the critical
factor was correlated with the age-related reduction in the
total oocyte pool or the number of antral follicles recruited
per cycle. The first tested this indirectly by comparing age
at menopause in women with a trisomic conception and
controls.27 The data appear to support the hypothesis. Wo-
men with trisomic spontaneous abortions had a mean age
at menopause a year younger than controls.
The second study tested the hypothesis more directly
by comparing hormonal measures of ovarian age and the
number of antral follicles per cycle seen by ultrasound in
women with trisomic and chromosomally normal spon-
taneous abortions. Results were negative with respect to
the antral pool size, and there was only a hint, not sta-
tistically significant, that the rise in FSH associated with
pool size occurred earlier in women with trisomic pregnan-
cies.28 Currently, we are studying skewed X inactivation
in women with karyotyped losses, following up on data
from Wendy Robinson and others, and we plan to re-
examine the FSH findings in this sample as well.
Meanwhile, on the laboratory front, the Human Ge-
nome Project was beginning to take shape. Under one of
the first Genome Project grants, my Ph.D. student Steve
Gersen and, later, my associate M. T. Yu set out to develop
a set of hamster-human hybrids, each of which contained
only one selectable human chromosome and was there-
fore useful for making chromosome-specific libraries and
for mapping cloned DNA.29 We also developed a chromo-
some 13–deletion hybrid-mapping panel,30 and I served
as the Genome Database Editor for chromosome 13 for
many years. Eventually, Columbia became the home of
the Genome Center for Chromosome 13, mapping a cos-
mid library derived from a 13-only hybrid.31 Unfortunate-
ly, this was one of the several blind alleys taken by the
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Genome Project, since it was later decided that clones de-
rived from hybrids did not make good sequencing material.
Now that we really do “have it all,” we are beginning
to reap the benefits. Projects that would have taken years
now take weeks. I retain my fascination with new tech-
nology and have recently begun collaborating with Mi-
chael Wigler at the Cold Spring Harbor Laboratory to use
genomic microarray analysis to detect small copy-number
changes in the genome. Cytogenetics has entered an ex-
citing era of “ultra high-resolution” chromosome analysis
via microarray, which is likely to have as big an impact
on human genetics as conventional cytogenetics did in
the past. It is likely that a significant proportion of un-
explained developmental pathology, as well as variation
within normal limits, may be due to such submicroscopic
changes. We are currently working on a project to examine
copy-number changes in children with congenital heart
disease, which again marries epidemiology with new tech-
nology. I look forward to an exciting next few years.
I will now turn to the third meaning of “Having it All.”
This is the opportunity that I have had throughout my
career to combine both clinical and research activities. I
have been as lucky in my clinical life as I have in my
research life, in having many long-time associates who are
responsible for making things work. I would like, in par-
ticular, to mention Judy Yu, who was my clinical labo-
ratory supervisor for 25 years and continues to work in
my research laboratory. My assistant Mary Walsh, whom
many of you know on the phone, has been the voice of
the laboratory to the world, kept me more or less orga-
nized, told me when it was time to get my hair done, and
always listened to my problems. My long-time clinical col-
laborator Kwame Anyane-Yeboa is a marvelous dysmor-
phologist, always interested in research projects that in-
volve his patients. The opportunity to interact directly with
patients, physicians, and genetics counselors has given me
great personal satisfaction over the years. While one may
see the same cytogenetic abnormality again and again, the
personalities and the circumstances involved in each fam-
ily situation are always different.
I have observed the evolution of clinical genetics from
a discipline focusing mostly on trying to make the correct
diagnosis in order to provide recurrence risks to family
members to one where we can offer prenatal and even
preimplantation diagnosis for a large number of condi-
tions and effective treatment for a few. I have also seen
society change, from a time when children with condi-
tions such as Down syndrome were routinely institution-
alized from birth to one that recognizes the importance
of maximizing potential for all children with disabilities.
A related change has been the emphasis on the protection
of human subjects used in research studies, something
that did not exist in the early days, when we could go out
to the large institutions for the mentally retarded in New
York and Connecticut and draw blood from anyone who
looked interesting.
Clinical cytogenetic laboratories have also changed a
great deal. In my first laboratory, there was just myself,
one technician, and no computers. Proficiency testing,
guidelines, and certifications were all nonexistent. How-
ever, I was introduced relatively early to the concept of
proficiency testing, since, under the guidance of Ernest
Hook, New York State pioneered in proficiency testing for
cytogenetics in 1974. For many years, I participated in the
review process and was impressed by the quality improve-
ment brought about by this initiative.
As Pat Jacobs mentioned in her introduction, the clin-
ical laboratory provides a constant source of new material
and new phenomena. Often, observations go undeveloped
and unexploited, so that I can say when someone else
takes it further “Oh yes, I remember seeing that once.”
However, there are other times when the clinical obser-
vations have led to something more. I will briefly mention
three of these.
First, more or less by chance, we studied a large number
of patients over a 10-year period who had chromosome
13 long-arm deletions and a wide variety of phenotypes.
It was striking that some 13 deletions gave very mild phe-
notypes and others very severe phenotypes, often involv-
ing holoprosencephaly. At the cytogenetic level, one could
define a region in band 13q32 that seemed to be deleted
in only the most severely affected patients. When a new
clinical fellow, Stephen Brown, arrived in the mid-’80s, he
followed up these observations in more detail, using the
molecular methods that were becoming available for com-
paring chromosomal deletions.32 Eventually, Steve suc-
ceeded in identifying in 13q32 a new gene, ZIC2, which
is essential for normal brain development and is mutated
in some patients with holoprosencephaly.33 His own lab
now tries to decipher the role of ZIC2 in development in
animal models, so this project has evolved all the way from
genotype-phenotype correlation to basic developmental
biology.
A second example was a fascinating patient of Kwame
Yeboa, for whom the original laboratory observations were
astonishing. This was a girl with profound mental retarda-
tion and microcephaly in whom we found cells with tri-
somy for virtually every human chromosome in lympho-
cyte cultures, skin cultures, and bone marrow. When we
wrote up this case,34 we suggested the condition be called
“mosaic variegated aneuploidy,” and this name seems to
have stuck. For many years, I pursued various leads trying
to decipher the basic cellular defect in this patient. Re-
cently, some cases of mosaic variegated aneuploidy have
been found to have mutations in BUB1B, a gene involved
in the spindle checkpoint.35 However, when we tested our
first patient, she turned out to have confounded us again,
because she has no mutation in this gene. Penny Jeggo’s
group has shown that there is a defective G2/M check-
point in the cell line,36 but mutation screening has been
negative for many candidates in this pathway. Someday,
I hope to learn the genetic basis for the mitotic error in
this patient.
A third example are the patients with marker chromo-
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somes now known to contain neocentromeres. These are
chromosomes with functional centromeres that do not
contain the original centromeric alpha satellite. Although
these chromosomes must have been observed for a very
long time in cytogenetic laboratories as uncharacterized
marker chromosomes, it was not until the availability of
alpha-satellite–specific FISH probes that their unique prop-
erties could be recognized. Because of my interest in chro-
mosome 13, cells with one of these chromosomes derived
from chromosome 13 were originally sent to us by Nancy
Carpenter. My son, Peter Warburton, did his graduate and
postdoctoral work on centromeres, and so we joined in
studying this and other cases that came my way. This led
to two publications on which we both appear as au-
thors.37,38 Peter is now on the faculty at Mt. Sinai, and he
and his wife, Alicia, continue to study the fascinating phe-
nomena of neocentromeres.39
My clinical involvement also inspired me to do some
population-based epidemiological studies to answer diffi-
cult questions that arose in counseling.
A recent study was prompted by a recurring clinical ques-
tion: does a woman with a trisomic spontaneous abortion,
particularly at a young age, have a sufficiently increased
risk for another trisomy that prenatal diagnosis would be
indicated? Our previous data based on spontaneous abor-
tions in the ’80s had failed to demonstrate this. However,
new data on prenatal diagnoses, collected in collaboration
with Louis Dallaire and Maya Thangavelu, both also for-
mer students of Clarke Fraser, strongly suggest an in-
creased risk for all trisomies among women with a pre-
vious trisomy, whether it be in a pregnancy loss or a pre-
natal diagnosis.40
I was originally asked to collect data on the clinical sig-
nificance of de novo rearrangements found at prenatal di-
agnosis, for a symposium at the International Congress of
Human Genetics held in Jerusalem in 1980. With the help
of a group of dedicated genetics counseling students and
the cooperation of many cytogeneticists across the con-
tinent, I continued to collect data on follow-up over a 10-
year period and finally published the results in 1991.41 This
paper remains one of the few to address this question in
a statistically valid way, which I say not as a boast but as
a complaint that so few data of this type are being col-
lected by cytogeneticists.
I am concerned that our knowledge of the clinical out-
come of cytogenetic changes is unable to keep up with
the exciting strides in our ability to detect new abnor-
malities and to define old ones more precisely. Very few
attempts are made to collect the kind of long-term clinical
data on outcome that are required for accurate counseling.
Even though such things as marker chromosomes may be
much better characterized, it often does not help the pa-
tient, since there is not enough data to predict the out-
come for most specifically defined markers. The situation
will only get worse as we explore the submicroscopic le-
sions defined by microarrays. Since this kind of research
is not very high tech, funding is difficult to obtain. I would
like to propose that organizations such as the American
College of Medical Genetics encourage and even provide
support for studies on the outcome of rare cytogenetic
anomalies after prenatal diagnosis. This is the only un-
biased source for prognostic data, and the ability to pool
resources and data on the Internet should make it much
easier than when I sent out my little questionnaire by mail.
Lastly, I will turn briefly to the more traditional meaning
of “Having It All”—as a woman who tries to combine
career and family. I am only the fifth female Allan Award
designee out of the total of 44. Does this mean that women
are not prominent in our Society? I would say obviously
not, both because I know so many distinguished women
in our profession and by looking around at this meeting.
Does it mean that women have faced problems in being
recognized for scientific achievements? I would say that
it does. Since the Allan Award is typically given to older
members of the society, it is to be hoped that the dearth
of female awardees reflects the prejudices of the past and
that the future will reflect the more equal opportunities
of the present.
Certainly, when I began in science, there were still major
barriers for women, regardless of whether they were also
facing the problems of trying to raise a family. Columbia
had a “nepotism” rule when I joined the faculty, so a man
and his wife could not both hold faculty appointments.
There was no question which one it would be. Most wo-
men in biology at Columbia, including some very eminent
ones, were hired on a non–tenure track, as was I. When
I finally did come up for tenure, I was turned down. For
a variety of reasons, I stayed at Columbia, since I had
financial support from both clinical work and grants.
I know from many conversations with younger female
colleagues that, while in many ways things are better than
when I began my career, women still face problems in
obtaining recognition. The recent report of the National
Academy of Sciences concludes, for example, that there
are still many ways in which the traditional academic sys-
tem impedes the advancement of women in science, often
in very subtle ways.
As was common at the time, I married a fellow student
when I was 21 and just beginning graduate school. My
husband, Toney, and I had three children before we left
Montreal for our first real jobs in New York. Our fourth
child was born 4 years later. I wish I could say that this
was all well planned and prescient on our part, but it really
was not that well thought out. Until the children were
grown, I necessarily worked a very regular 8-hour day. We
had dinner every night as a family, promptly at 6:30, and
take-out and order-in were not the options they are today.
Some of my fondest memories are of our traditional ’70s
family vacations, traveling in the family car and camping.
On one memorable trip in 1973, we traveled with four
children and my mother across the U.S., from New York
to San Francisco and back, in a forerunner of the SUV that
we called the “Big Green Machine.” This is a part of my
life that I treasure, and I wouldn’t have had it any other
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Table 4. Consecutive Karyotyped Spontaneous Abortions from Two Time
Periods
Finding
New York City
1975–1986
Ridgewood, NJ
2003–2005
No. karyotyped 2,821 479
Percentage chromosomally abnormal 44.8 68.3
Percentage trisomica 26.1 43.8
Percentage of single trisomies:
Trisomy 16′ 30.1 28.1
Trisomies of acrocentric chromosomes 33.8 47.4
Double and triple trisomies 3.5 6.2
Mean maternal age at last menstrual period (years) 28.1 34.7
* Includes mosaics, sex-chromosome trisomies, and multiple trisomies.
way. I don’t remember feeling constantly exhausted, nor
do I think my professional life suffered much from the
times the family came first. In retrospect, I believe one of
the reasons is that my husband and I had the energy and
enthusiasm of youth. The one tragedy of my live was the
death of my oldest daughter at the age of 21. The three
other children all now live in the New York area, where
I am lucky enough to be able to see them and my three
terrific grandchildren quite often.
The more common path today is for women to post-
pone childbearing to a time when they feel they have
already become established in their careers, usually after
the age of 35. The proportion of all U.S. births to women
over 35 has tripled in the last 20 years,42 and this statistic
is much more exaggerated among professional women.
Since I have spent a large part of my professional life pon-
dering the association of maternal age with pregnancy loss
and trisomy, this change in the pattern of childbearing
concerns me.
By the time a woman has reached 35, 30% of her oocytes
will have a numerical error, and this figure approaches
50% by the time she is 40. The resulting high rate of ap-
parent infertility and miscarriages, need for prenatal di-
agnosis, and increased reliance on assisted reproduction
not only lead to high anxiety and sometimes despair for
couples trying to have a family but also consume health-
care resources. Desperate couples are also easy prey for less-
than-scrupulous providers of reproductive technologies
that are either not needed or have no proven value. Much
of this distress could be avoided if women had their chil-
dren at a younger age.
Table 4 shows the amazing effect of maternal age on
reproductive loss, from two surveys of karyotype in spon-
taneous abortions, the first in the ’70s and ’80s, the second
more recently. With a 7-year increase in mean maternal
age at miscarriage, the proportion of losses with trisomy
has doubled, from 23% to 46%.
Our expectancy for productive and healthy life has in-
creased by many years, so that a woman can look forward,
if she wishes, to continuing in her chosen career beyond
the age of 70. However, at least so far, we have not learned
how to reprogram a woman’s biological clock, nor to turn
off her desire to nurture her children. I believe we need
to rethink the current path for women wishing to have
both children and a career in science or elsewhere. First,
young women should be better educated concerning the
very real problems they may face if they delay childbear-
ing, so that they can at least weigh the options with an
understanding of the facts. Second, it may be possible for
the career paths of men and women to be different but
equal. It could become the norm for women who wish to
have children to take time between finishing their edu-
cation and working full time, when they can slow down
their career paths for a while. True, men at the same age
would be further ahead, but this would not matter if women
could routinely rejoin the same path with the expectation
of continuing longer. A tax structure that provided relief
for young families would be an incentive, as would hiring
practices that encouraged women who chose this path to
stay in touch with their fields during the hiatus.
I hope I have been able to convey what great fun it has
been to be a part of the remarkable journey of human
genetics over the past 45 years. An important part of that
trip has been my participation in the activities of the
American Society of Human Genetics and the extraordi-
nary people that I can count as my friends and associates.
I think I have attended every meeting since my first in
1964, with the exception of 1967, when I was about to
deliver my last child, and 2005, when I was about to de-
liver my last grant proposal. In 1980, when the meetings
were still being organized by a local committee at the
meeting site rather than by professional meeting planners,
Arthur Bloom offered to host the meeting in New York
City. I discovered that this meant I was expected to run
the nonscientific parts of the meeting. I was in charge of
all the arrangements, including booking the hotel and
setting and collecting the registration fee. This was $65
for members and included the traditional banquet and
dance on the night the Allan Award was presented. The
dance, at least, is something I am sorry to see has now
disappeared from the schedule. I still remember the sink-
ing sensation when, as we sat at the head banquet table,
the maitre d’ of the Hilton brought me the check for the
banquet for 1,000 people. It was bigger than what I had
paid for my house some 10 years before! I took a deep
breath and signed my name at the bottom. Then, having
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discovered that we were going to have a surplus of funds
due to an unexpectedly large turnout, I ordered an open
bar for the dance. Many people have told me that they
remember that meeting as one of the best!
Because of my long association with the society and its
members, I am very touched and enormously grateful for
this award from my peers. Thank you so much for making
this one of the best moments of my life.
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